Geminor M 4 Forte Tablet PR is a combination oral hypoglycemic agent containing Glimepiride 4 mg and Metformin 1000 mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, improves insulin sensitivity by decreasing hepatic glucose production and enhancing peripheral glucose uptake. The prolonged-release formulation ensures a steady release of active ingredients, promoting better glycemic control with reduced gastrointestinal side effects commonly associated with immediate-release metformin. Geminor M 4 Forte is prescribed as part of a comprehensive diabetes management plan, including diet, exercise, and regular monitoring of blood glucose levels. It is particularly beneficial for patients inadequately controlled on monotherapy or those requiring combination therapy to achieve target glycemic goals. Caution is advised in patients with renal impairment, hepatic dysfunction, or conditions predisposing to lactic acidosis. Common adverse effects may include hypoglycemia, gastrointestinal disturbances, and rarely, lactic acidosis. Regular monitoring of renal function and blood glucose is recommended during therapy. This medication should be used under medical supervision with adherence to prescribed dosage and lifestyle modifications.